BioSpace News Archive

In an effort to understand aging, researchers from Stanford University and colleagues around the world analyzed almost 3,000 proteins in the blood of more than 4,000 people ages 18 to 94.

If you’re having trouble finding your confidence again, try these tips for regaining a (healthy) ego.

GlaxoSmithKline announced results from its pivotal DREAMM-2 Phase III trial of belantamab mafodotin in multiple myeloma.

The same shoe size fits everyone with similar feet, but this approach doesn’t work so well for medical treatment.

The deal allows Novoheart to merge its MyHeart Platform with Harvard’s tissue-engineered scale model of the heart ventricle and bioreactor technology.

BioAscent scientists, working in collaboration with teams at the German Cancer Research Center and the Pivot Park Screening Centre as part of the European Lead Factory project, have helped to discover potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.

Latest funding caps year of groundbreaking milestones for transformative vascular access company; new capital will be used to meet rapidly growing hospital and patient demand

With the latest approval, Xtandi, an androgen receptor inhibitor, is now the only oral treatment approved by the FDA for three distinct types of advanced prostate cancer – non-metastatic and metastatic castration-resistant prostate cancer (CRPC) and mCSPC.

Almost one month after BeiGene’s Bruton’s kinase inhibitor Brukinsa won accelerated approval for mantle cell lymphoma, the company reported the drug failed to hit the mark in a late-stage trial assessing the drug as a treatment for Waldenström’s macroglobulinemia.

The trial met its primary efficacy endpoint and all tested secondary endpoints.